Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Posaconazole

FDA-approved product (suspension, oral), marketed as Noxafil, Noxafil Powdermix Kit, Posaconazole.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Posaconazole
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Aspergillosis
  • Candidiasis
  • Coccidioidomycosis
  • Fungal infectious disease
  • Neutropenia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Triazole and tetrazole derivatives
FDA pharmacologic class
Azole Antifungal FDA label ↗
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J02AC04; FDA class Azole Antifungal

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA, K. pneumoniae and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA72.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli53.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae44.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis63.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Posaconazole in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Posaconazole with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Study of Monzosertib In Patients With R/R AML Or High-Risk Myelodysplastic Syndrome

    NCT07780565 · start 2027-01-01

    Registered record
    Registry ID
    NCT07780565
    Conditions
    Acute Myeloid Leukemia (AML); Myelodysplastic Syndrome
    Interventions
    Monzosertib; Posaconazole; Isavuconazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Not yet recruiting
    Start
    2027-01-01
    Completion
    2031-08-30
    Enrolment
    42

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Myeloid Leukemia (AML); Myelodysplastic Syndrome
    InterventionMonzosertib; Posaconazole; Isavuconazole
    PhasePhase 1
    Registry statusNot yet recruiting

  • A Study of Itraconazole and Posaconazole for Chronic Pulmonary Aspergillosis

    NCT07825259 · start 2026-11-01

    Registered record
    Registry ID
    NCT07825259
    Conditions
    Chronic Pulmonary Aspergillosis
    Interventions
    Posaconazole Delayed Release Oral Tablet; Itraconazole (ITZ)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Not yet recruiting
    Start
    2026-11-01
    Completion
    2029-12-31
    Enrolment
    220

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Pulmonary Aspergillosis
    InterventionPosaconazole Delayed Release Oral Tablet; Itraconazole (ITZ)
    PhasePhase 3
    Registry statusNot yet recruiting

  • Histoplasmosis Induction and Consolidation Therapy Factorial Randomized Clinical Trial (Histo-FACT)

    NCT07261150 · start 2026-10-01

    Registered record
    Registry ID
    NCT07261150
    Conditions
    Histoplasmosis
    Interventions
    LAmB B; Posaconazole; World Health Organization (WHO)-recommended SOC; WHO-recommended SOC Itraconazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Not yet recruiting
    Start
    2026-10-01
    Completion
    2030-12-31
    Enrolment
    664

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHistoplasmosis
    InterventionLAmB B; Posaconazole; World Health Organization (WHO)-recommended SOC; WHO-recommended SOC Itraconazole
    PhasePhase 3
    Registry statusNot yet recruiting

  • Revumenib, Azacitidine, and VENetoclax in Newly Diagnosed KMT2A-Rearranged AML

    NCT07605949 · start 2026-10

    Registered record
    Registry ID
    NCT07605949
    Conditions
    Leukemia Acute Myeloid
    Interventions
    Azacitidine; Venetoclax; Revumenib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-10
    Completion
    2028-07
    Enrolment
    88

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLeukemia Acute Myeloid
    InterventionAzacitidine; Venetoclax; Revumenib
    PhasePhase 2
    Registry statusNot yet recruiting

  • A Study to Evaluate S241656 Alone or in Combination in Participants With Selected Myeloid Malignancies

    NCT07719348 · start 2026-09-15

    Registered record
    Registry ID
    NCT07719348
    Conditions
    Acute Myeloid Leukemia; Chronic Myelomonocytic Leukemia; Myelodysplastic Syndrome Acute Myeloid Leukemia
    Interventions
    S241656; Posaconazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-09-15
    Completion
    2030-09-30
    Enrolment
    64

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Myeloid Leukemia; Chronic Myelomonocytic Leukemia; Myelodysplastic Syndrome Acute Myeloid Leukemia
    InterventionS241656; Posaconazole
    PhasePhase 1 / Phase 2
    Registry statusNot yet recruiting

  • Fludarabine Plus Melphalan Versus Addition of Venetoclax to Fludarabine/Melphalan Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in AML/MDS Patients Aged > 50 Years: a Multicenter, Randomized, Phase 3 Trial

    NCT07396480 · start 2026-03-01

    Registered record
    Registry ID
    NCT07396480
    Conditions
    Venentoclax; Myeloid Malignancies; Conditioning; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; Acute Myeloid Leucemia; Myeldysplastic Syndrome (MDS)
    Interventions
    Venetoclax in combination with fludarabine and melphalan; Fludarabine and Melphalan
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2026-03-01
    Completion
    2030-06-30
    Enrolment
    186

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVenentoclax; Myeloid Malignancies; Conditioning; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION +2 more
    InterventionVenetoclax in combination with fludarabine and melphalan; Fludarabine and Melphalan
    PhasePhase 3
    Registry statusRecruiting

  • Venetoclax-Enhanced BUCY vs. Standard BUCY Conditioning in High-Risk AML and MDS Patients Undergoing Allo-HSCT (Ven-BUCY Study)

    NCT07183878 · start 2025-08-20

    Registered record
    Registry ID
    NCT07183878
    Conditions
    Acute Myeloid Leukemia; High-Risk Acute Myeloid Leukemia; Myelodysplastic Syndromes; High-Risk Myelodysplastic Syndromes
    Interventions
    Venetoclax; None-placebo; Busulfan (BU)
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2025-08-20
    Completion
    2028-08-20
    Enrolment
    138

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Myeloid Leukemia; High-Risk Acute Myeloid Leukemia; Myelodysplastic Syndromes; High-Risk Myelodysplastic Syndromes
    InterventionVenetoclax; None-placebo; Busulfan (BU)
    PhaseNot applicable
    Registry statusRecruiting

  • Liposomal Amphotericin B and Isavuconazole/Posaconazole in Br-IFD（ Breakthrough Invasive Fungal Disease） in Patients With Malignant Hematological Diseases

    NCT07135778 · start 2025-05-19

    Registered record
    Registry ID
    NCT07135778
    Conditions
    Invasive Fungal Disease
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2025-05-19
    Completion
    2026-12-31
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInvasive Fungal Disease
    InterventionNot recorded
    PhaseNot recorded
    Registry statusRecruiting

  • Liposomal Amphotericin B Plus Posaconazole/Isavuconazole for Mucormycosis in Hematologic Malignancies: Efficacy and Safety

    NCT07185503 · start 2025-03-25

    Registered record
    Registry ID
    NCT07185503
    Conditions
    Mucormycosis in Hematologic Malignancies
    Interventions
    liposomal amphotericin B (3-5 mg/kg/day) combined with posaconazole/isavuconazole
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2025-03-25
    Completion
    2027-01
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMucormycosis in Hematologic Malignancies
    Interventionliposomal amphotericin B (3-5 mg/kg/day) combined with posaconazole/isavuconazole
    PhaseNot recorded
    Registry statusRecruiting

  • Treatment Duration of IPA

    NCT06583512 · start 2024-12-01

    Registered record
    Registry ID
    NCT06583512
    Conditions
    Invasive Aspergillosis; Antifungal Therapy
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Active not recruiting
    Start
    2024-12-01
    Completion
    2026-08-31
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInvasive Aspergillosis; Antifungal Therapy
    InterventionNot recorded
    PhaseNot recorded
    Registry statusActive not recruiting

  • Study of Posaconazole Prophylaxis in Patients Receiving Hematopoietic Stem Cell Allograft (Allo-HSC) at High Risk of Invasive Fungal Infection (IFI)

    NCT06541067 · start 2024-11-08

    Registered record
    Registry ID
    NCT06541067
    Conditions
    Hematologic Malignancy
    Interventions
    Posaconazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2024-11-08
    Completion
    2028-11-08
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHematologic Malignancy
    InterventionPosaconazole
    PhasePhase 2
    Registry statusRecruiting

  • A Multicenter RCT of "3+7" vs Venetoclax + CACAG in Newly Diagnosed Mid/High-Risk AML Patients

    NCT06928376 · start 2024-04-18

    Registered record
    Registry ID
    NCT06928376
    Conditions
    Acute Myeloid Leukemia; First Line Therapy
    Interventions
    Azacytidine; Cytarabine; Aclacinomycin; Chidamide; Venetoclax; Granulocyte colony-stimulating factor; "3+7"
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2024-04-18
    Completion
    2026-09-01
    Enrolment
    160

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Myeloid Leukemia; First Line Therapy
    InterventionAzacytidine; Cytarabine; Aclacinomycin; Chidamide +3 more
    PhasePhase 2
    Registry statusRecruiting

  • Posaconazole Tablet As Primary Prophylaxis of HSCT Patients with Gastrointestinal GVHD

    NCT06698211 · start 2023-08-01

    Registered record
    Registry ID
    NCT06698211
    Conditions
    Invasive Fungal Disease; Graft Versus Host Disease; Hematopoietic Stem Cell Transplantation
    Interventions
    Posaconazole tablet
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Enrolling by invitation
    Start
    2023-08-01
    Completion
    2025-01-01
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInvasive Fungal Disease; Graft Versus Host Disease; Hematopoietic Stem Cell Transplantation
    InterventionPosaconazole tablet
    PhaseNot recorded
    Registry statusEnrolling by invitation

  • Venetoclax Plus CACAG Regimen for Newly Diagnosed Acute Myeloid Leukemia

    NCT06068621 · start 2023-03-01

    Registered record
    Registry ID
    NCT06068621
    Conditions
    Acute Myeloid Leukemia
    Interventions
    Azacytidine; Cytarabine; Aclacinomycin; Chidamide; Venetoclax; Granulocyte colony-stimulating factor; "3+7"
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2023-03-01
    Completion
    2025-08-31
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Myeloid Leukemia
    InterventionAzacytidine; Cytarabine; Aclacinomycin; Chidamide +3 more
    PhasePhase 2
    Registry statusCompleted

  • Amphotericin Versus Posaconazole for Pulmonary Mucormycosis

    NCT05468372 · start 2022-07-01

    Registered record
    Registry ID
    NCT05468372
    Conditions
    Mucormycosis; Pulmonary (Etiology)
    Interventions
    Posaconazole 600 mg followed by posaconazole 300 mg once daily; Liposomal Amphotericin B
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2022-07-01
    Completion
    2026-02-01
    Enrolment
    82

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMucormycosis; Pulmonary (Etiology)
    InterventionPosaconazole 600 mg followed by posaconazole 300 mg once daily; Liposomal Amphotericin B
    PhasePhase 2
    Registry statusCompleted